1,600 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by Park Place Capital Corp

Park Place Capital Corp bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,600 shares of the company’s stock, valued at approximately $46,000.

Several other hedge funds also recently made changes to their positions in PCRX. Texas Permanent School Fund Corp increased its position in Pacira BioSciences by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 40,642 shares of the company’s stock valued at $1,188,000 after purchasing an additional 543 shares during the period. Illinois Municipal Retirement Fund increased its position in Pacira BioSciences by 2.2% during the 4th quarter. Illinois Municipal Retirement Fund now owns 26,964 shares of the company’s stock valued at $910,000 after purchasing an additional 591 shares during the period. Duality Advisers LP increased its position in Pacira BioSciences by 1.8% during the 1st quarter. Duality Advisers LP now owns 34,784 shares of the company’s stock valued at $1,016,000 after purchasing an additional 605 shares during the period. Inspire Investing LLC increased its position in Pacira BioSciences by 5.9% during the 1st quarter. Inspire Investing LLC now owns 12,131 shares of the company’s stock valued at $354,000 after purchasing an additional 675 shares during the period. Finally, Quadrant Capital Group LLC increased its position in Pacira BioSciences by 61.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company’s stock valued at $78,000 after purchasing an additional 885 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PCRX has been the topic of a number of research analyst reports. Royal Bank of Canada reduced their price objective on shares of Pacira BioSciences from $42.00 to $37.00 and set an “outperform” rating on the stock in a research report on Wednesday. Truist Financial dropped their target price on shares of Pacira BioSciences from $45.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. HC Wainwright restated a “buy” rating and set a $57.00 target price on shares of Pacira BioSciences in a report on Tuesday, July 2nd. Barclays cut shares of Pacira BioSciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $38.00 to $25.00 in a report on Wednesday, July 3rd. Finally, Raymond James dropped their target price on shares of Pacira BioSciences from $41.00 to $37.00 and set an “outperform” rating on the stock in a report on Wednesday. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $41.44.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX traded up $0.51 during trading on Friday, reaching $21.26. 942,336 shares of the company traded hands, compared to its average volume of 1,160,541. The firm has a 50 day simple moving average of $25.03 and a 200-day simple moving average of $27.80. The company has a quick ratio of 4.78, a current ratio of 6.82 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $980.72 million, a PE ratio of 14.87 and a beta of 0.88. Pacira BioSciences, Inc. has a 52-week low of $19.34 and a 52-week high of $40.16.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The company had revenue of $167.12 million for the quarter, compared to analysts’ expectations of $165.43 million. Equities research analysts anticipate that Pacira BioSciences, Inc. will post 2.13 earnings per share for the current year.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, COO Daryl Gaugler sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $28.38, for a total transaction of $28,380.00. Following the sale, the chief operating officer now owns 116,040 shares in the company, valued at approximately $3,293,215.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Pacira BioSciences news, COO Daryl Gaugler sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $28.38, for a total transaction of $28,380.00. Following the sale, the chief operating officer now owns 116,040 shares in the company, valued at approximately $3,293,215.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jonathan Slonin sold 2,836 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total transaction of $80,117.00. Following the sale, the insider now owns 95,557 shares in the company, valued at approximately $2,699,485.25. The disclosure for this sale can be found here. Insiders have sold 22,095 shares of company stock worth $621,118 in the last quarter. Company insiders own 6.40% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.